Amgen news from FierceBiotech
NewsWall Street swoons over Amgen's D-mab future
It's been a long time since I've heard the words love and Amgen in one sentence, but that's the approach the Los Angeles Times took in covering Wall Street's enthusiastic response to D-mab's Read more...
Amgen shares buoyed by late-stage D-mab data
Amgen issued some eagerly awaited late-stage data on its bone drug denosumab which demonstrated a lower risk of spine and hip fractures among women with osteoporosis. Investors rallied behind the Read more...
Amgen and Takeda - Billion-dollar deals
Who: AmgenWith: TakedaWhat: $1 billion licensing deal Scoop: 2007 was a rough year for Amgen. Safety problems plagued the company's bestselling anemia drugs Aranesp and Epogen, causing sales of the Read more...
FDA expected to act soon on Amgen’s Nplate
It's down to the nail-biting stage of drug discovery for Amgen's Nplate team. Analysts say they expect a formal decision from the FDA on the blood-clotting drug by tomorrow. And with the endorsement Read more...
Amgen releases positive denosumab results
Amgen is publishing positive data today for its closely watched Phase III trial of denosumab for the treatment of bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate Read more...
Denosumab - Next gen biotech blockbusters
Drug: DenosumabCompany: Amgen Scoop: Denosumab is a fully-human monoclonal antibody which Amgen is studying for a number of indications, including osteoporosis, treatment-induced bone loss, bone Read more...
Amgen drug positive in cancer trial
Amgen was buoyed by the news that new data demonstrates that motesanib slowed the progression of metastatic thyroid cancer. Out of 93 patients in the study, 49 had a positive response. Volunteers Read more...
Amgen's D-mab beats Fosamax in trial
In a head-to-head trial, Amgen's twice-yearly osteoporosis drug denosumab outperformed weekly oral doses of Merck's Read more...
A deluge of pre-ASCO data hits the market
As we mentioned earlier this week, data from almost 5,000 clinical studies was released last night in preparation for next week's ASCO meeting. And some of the most interesting data won't be released Read more...
Amgen CEO: "I felt real economic pain"
What do you do when your biggest therapeutic earners are swooning, your stock price is down and analysts have turned scornful? Look for that silver lining. That was Read more...
| Press ReleasesFDA Receives New Data on Risks of Anemia Drugs FDA Receives New Data on Risks of Anemia Drugs Consistent With Previous Data on Tumor Growth and Death The U.S. Food and Drug Administration (FDA) is reviewing new data from two studies that provide Read more... PRESS RELEASE: Amgen Pivotal Phase 3 Data Show Denosumab Increased Bone Density Throughout Skeleton in Non-Metastatic Breast Can Amgen Pivotal Phase 3 Data Show Denosumab Increased Bone Density Throughout Skeleton in Non-Metastatic Breast Cancer Patients on Adjuvant Aromatase Inhibitor Therapy SAN ANTONIO -- Amgen today Read more... PRESS RELEASE: Pivotal Phase 3 Romiplostim Study in Splenectomized Patients Meets Primary Endpoints Pivotal Phase 3 Romiplostim Study in Splenectomized Patients Meets Primary Endpoints Data Show Romiplostim Increased and Sustained Platelet Counts in Splenectomized Adult Patients with Immune Read more... PRESS RELEASE: Amgen Announces Interim Results of Aranesp ''PREPARE'' Study in Breast Cancer Patients Amgen Announces Interim Results of Aranesp ''PREPARE'' Study in Breast Cancer Patients THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen, Inc. (NASDAQ: AMGN - News) today announced that it had received Read more... PRESS RELEASE: FDA approves Mircera: first renal anemia treatment in the US with monthly maintenance dosing FDA approves Mircera: first renal anemia treatment in the US with monthly maintenance dosing Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Mircera (methoxy Read more... |
Get more Amgen coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets